Owkin signs licensing deal with Boehringer Ingelheim for AI drug discovery
Owkin said it signed a licensing deal with Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-related diseases.
AI company Owkin said on Wednesday it has signed a licensing deal with Germany's Boehringer Ingelheim, giving the drugmaker access to its AI research platform and patient data to speed up discovery of drugs for cancer and immunity-related diseases. The agreement adds Boehringer to a growing list of pharma companies working with Owkin, which uses machine learning to analyze medical data.